JD Health 2H 2025 Results Projected to Beat Market Expectations -- Market Talk

Dow Jones01-06

0853 GMT - JD Health's 2H 2025 results should beat estimates, driven by stronger pharmaceutical demand following a spike in influenza cases last quarter, Nomura analysts Rachel Guo and Jialong Shi say in a note. The company's 4Q 2025 revenue is projected to show 22% on-year growth, supported by sales growth in pharmaceuticals, nutrition and medical devices, with effective marketing boosting nutrition brands. Its 4Q operating profit margin is estimated to rise 0.9 percentage point on year, helped by enhanced supply-chain capabilities and rapid growth in high-margin advertising revenue. Nomura raises its 2025-2026 earnings forecasts by 1% on stronger revenue growth expectations. It maintains a buy rating and HK$80 target price on the stock, which last closed at HK$61.35. (jason.chau@wsj.com)

(END) Dow Jones Newswires

January 06, 2026 03:53 ET (08:53 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2601860373?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-06 16:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601860373","market":"us","top_or_hot":-1,"title":"JD Health 2H 2025 Results Projected to Beat Market Expectations -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0853 GMT - <a href=\"https://laohu8.com/S/JD\">JD</a> Health's 2H 2025 results should beat estimates, driven by stronger pharmaceutical demand following a spike in influenza cases last quarter, Nomura analysts Rachel Guo and Jialong Shi say in a note. The company's 4Q 2025 revenue is projected to show 22% on-year growth, supported by sales growth in pharmaceuticals, nutrition and medical devices, with effective marketing boosting nutrition brands. Its 4Q operating profit margin is estimated to rise 0.9 percentage point on year, helped by enhanced supply-chain capabilities and rapid growth in high-margin advertising revenue. Nomura raises its 2025-2026 earnings forecasts by 1% on stronger revenue growth expectations. It maintains a buy rating and HK$80 target price on the stock, which last closed at HK$61.35. (jason.chau@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 06, 2026 03:53 ET (08:53 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>JD Health 2H 2025 Results Projected to Beat Market Expectations -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJD Health 2H 2025 Results Projected to Beat Market Expectations -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-06 16:53</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0853 GMT - <a href=\"https://laohu8.com/S/JD\">JD</a> Health's 2H 2025 results should beat estimates, driven by stronger pharmaceutical demand following a spike in influenza cases last quarter, Nomura analysts Rachel Guo and Jialong Shi say in a note. The company's 4Q 2025 revenue is projected to show 22% on-year growth, supported by sales growth in pharmaceuticals, nutrition and medical devices, with effective marketing boosting nutrition brands. Its 4Q operating profit margin is estimated to rise 0.9 percentage point on year, helped by enhanced supply-chain capabilities and rapid growth in high-margin advertising revenue. Nomura raises its 2025-2026 earnings forecasts by 1% on stronger revenue growth expectations. It maintains a buy rating and HK$80 target price on the stock, which last closed at HK$61.35. (jason.chau@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 06, 2026 03:53 ET (08:53 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4509","symbol_name":"腾讯概念","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2601860373","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601860373","pubTimestamp":1767689580,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0853 GMT - JD Health's 2H 2025 results should beat estimates, driven by stronger pharmaceutical demand following a spike in influenza cases last quarter, Nomura analysts Rachel Guo and Jialong Shi say in a note. The company's 4Q 2025 revenue is projected to show 22% on-year growth, supported by sales growth in pharmaceuticals, nutrition and medical devices, with effective marketing boosting nutrition brands. Its 4Q operating profit margin is estimated to rise 0.9 percentage point on year, helped by enhanced supply-chain capabilities and rapid growth in high-margin advertising revenue. Nomura raises its 2025-2026 earnings forecasts by 1% on stronger revenue growth expectations. It maintains a buy rating and HK$80 target price on the stock, which last closed at HK$61.35. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"86618":"京东健康-R","BK4509":"腾讯概念","SGXZ62798434.SGD":"MAYBANK ASIAN GROWTH AND INCOME-I \"A\" (SGDHDG) ACC","BK4220":"综合零售","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","BK4524":"宅经济概念","BK1615":"港股-互联网","IE00BGV7N243.SGD":"FSSA Global Emerging Markets Focus I Acc SGD","LU0106959298.USD":"UBS (LUX) EQUITY FUND - EMERGING MARKETS SUSTAINABLE LEADERS (USD) \"P\" (USD) ACC","BK1589":"北水核心资产","BK4579":"人工智能","BK4531":"中概回港概念","LU0463099449.HKD":"SCHRODER ISF CHINA OPPORTUNITIES \"A\" (HKD) ACC","BK1515":"抗疫概念","06618":"京东健康","BK4526":"热门中概股","BK4585":"ETF&股票定投概念","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","BK4503":"景林资产持仓","BK1247":"药品零售","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","BK1583":"高瓴概念","HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","BK4122":"互联网与直销零售","BK4558":"双十一","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","BK1591":"就地过年概念","LU1188198961.HKD":"SCHRODER ISF CHINA OPPORTUNITIES \"A\" (HKD) INC QV","BK4505":"高瓴资本持仓","LU1880383366.USD":"东方汇理中国股票基金 A2 (C)","LU0244354667.USD":"SCHRODER ISF CHINA OPPORTUNITIES \"A\" ACC","BK4504":"桥水持仓","BK1571":"互联网医疗","LU0051755006.USD":"摩根大通中国A (dist)","LU1688375341.USD":"贝莱德中国灵活股票基金","SG9999002463.SGD":"LionGlobal China Growth SGD","IE0008368742.USD":"首域中国增长基金I Acc","BK4614":"Manus概念股","BK4588":"碎股","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","BK1142":"互联网与直销零售","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","LU0456827905.SGD":"JPMorgan Funds - China A (acc) SGD","SGXZ86797644.SGD":"MAYBANK ASIAN GROWTH AND INCOME-I \"A\" (SGDHDG) INC","BK4551":"寇图资本持仓"},"translate_title":"京东健康2025年下半年业绩预计将超出市场预期——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"86618":0.6,"06618":1.95},"content_text":"0853 GMT - JD Health's 2H 2025 results should beat estimates, driven by stronger pharmaceutical demand following a spike in influenza cases last quarter, Nomura analysts Rachel Guo and Jialong Shi say in a note. The company's 4Q 2025 revenue is projected to show 22% on-year growth, supported by sales growth in pharmaceuticals, nutrition and medical devices, with effective marketing boosting nutrition brands. Its 4Q operating profit margin is estimated to rise 0.9 percentage point on year, helped by enhanced supply-chain capabilities and rapid growth in high-margin advertising revenue. Nomura raises its 2025-2026 earnings forecasts by 1% on stronger revenue growth expectations. It maintains a buy rating and HK$80 target price on the stock, which last closed at HK$61.35. (jason.chau@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 06, 2026 03:53 ET (08:53 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.1","shortVersion":"4.36.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2601860373","isCrawlerRequest":true}